Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer
NCT00183794Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Nov 2002
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in ovarian cancer and primary peritoneal carcinoma (PPC), sponsored by University of Southern California. Primary endpoint: Tumor Response Type at 6 months. Started Nov 2002; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00183794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183794.